A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Public ClinicalTrials.gov record NCT05451849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Study identification
- NCT ID
- NCT05451849
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- TCR2 Therapeutics
- Industry
- Enrollment
- 6 participants
Conditions and interventions
Conditions
- Cholangiocarcinoma
- Colorectal Cancer
- Colorectal Neoplasms
- Mesothelioma
- Mesothelioma Peritoneum
- Mesothelioma, Malignant
- Mesotheliomas Pleural
- Non Small Cell Lung Cancer
- Ovarian Adenocarcinoma
- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Serous Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
- Pancreatic Neoplasms
- TNBC - Triple-Negative Breast Cancer
- Triple Negative Breast Cancer
Interventions
- Cyclophosphamide Drug
- Fludarabine Drug
- TC-510 Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2022
- Primary completion
- Oct 29, 2028
- Completion
- Oct 29, 2028
- Last update posted
- Aug 26, 2025
2022 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | — |
| University of Miami | Miami | Florida | 33146 | — |
| National Cancer Institute | Bethesda | Maryland | 20814 | — |
| University of Minnesota, Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Montefiore Einstein Cancer Center | The Bronx | New York | 10461 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05451849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2025 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05451849 live on ClinicalTrials.gov.